Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(1.07)
# 3,807
Out of 5,172 analysts
337
Total ratings
25.74%
Success rate
-14.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PPBT Purple Biotech | Maintains: Buy | $34 → $30 | $3.98 | +653.77% | 15 | Mar 13, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $9 → $7 | $3.75 | +86.67% | 3 | Mar 10, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $36 → $38 | $14.08 | +169.89% | 24 | Mar 9, 2026 | |
| SANA Sana Biotechnology | Maintains: Buy | $9 → $7 | $3.11 | +125.08% | 13 | Mar 4, 2026 | |
| ANAB AnaptysBio | Maintains: Buy | $51 → $66 | $62.37 | +5.83% | 14 | Mar 4, 2026 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 | $21.64 | +47.87% | 8 | Mar 2, 2026 | |
| NVCR NovoCure | Maintains: Buy | $47 → $49 | $11.81 | +314.90% | 22 | Feb 26, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $115 | $114.77 | +0.20% | 15 | Feb 23, 2026 | |
| AUTL Autolus Therapeutics | Initiates: Buy | $9 | $1.37 | +556.93% | 1 | Feb 17, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $62 → $65 | $27.86 | +133.31% | 5 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $47 | $36.00 | +30.56% | 3 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $1.66 | +1,044.58% | 13 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $15 | $5.32 | +181.95% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $5 | $2.88 | +73.61% | 13 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.92 | +1,204.35% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $60 | $30.07 | +99.53% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.18 | - | 14 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.71 | +519.95% | 20 | Sep 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $4.18 | +856.94% | 15 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $35 | $9.41 | +271.94% | 14 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $0.56 | +1,335.24% | 25 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $20 | $1.23 | +1,526.02% | 10 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $9.99 | +260.36% | 9 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $560 → $280 | $8.98 | +3,018.04% | 17 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.81 | +184.70% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $2.40 | +1,150.00% | 7 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.14 | +741.12% | 15 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $183 | $2.87 | +6,262.72% | 12 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $5.33 | +556.66% | 14 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.46 | - | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $2.13 | - | 1 | Apr 25, 2024 |
Purple Biotech
Mar 13, 2026
Maintains: Buy
Price Target: $34 → $30
Current: $3.98
Upside: +653.77%
SAB Biotherapeutics
Mar 10, 2026
Maintains: Buy
Price Target: $9 → $7
Current: $3.75
Upside: +86.67%
Olema Pharmaceuticals
Mar 9, 2026
Maintains: Buy
Price Target: $36 → $38
Current: $14.08
Upside: +169.89%
Sana Biotechnology
Mar 4, 2026
Maintains: Buy
Price Target: $9 → $7
Current: $3.11
Upside: +125.08%
AnaptysBio
Mar 4, 2026
Maintains: Buy
Price Target: $51 → $66
Current: $62.37
Upside: +5.83%
Arcus Biosciences
Mar 2, 2026
Reiterates: Buy
Price Target: $32
Current: $21.64
Upside: +47.87%
NovoCure
Feb 26, 2026
Maintains: Buy
Price Target: $47 → $49
Current: $11.81
Upside: +314.90%
Arcellx
Feb 23, 2026
Downgrades: Neutral
Price Target: $115
Current: $114.77
Upside: +0.20%
Autolus Therapeutics
Feb 17, 2026
Initiates: Buy
Price Target: $9
Current: $1.37
Upside: +556.93%
Agios Pharmaceuticals
Feb 12, 2026
Maintains: Buy
Price Target: $62 → $65
Current: $27.86
Upside: +133.31%
Dec 19, 2025
Maintains: Buy
Price Target: $36 → $47
Current: $36.00
Upside: +30.56%
Nov 25, 2025
Reiterates: Buy
Price Target: $19
Current: $1.66
Upside: +1,044.58%
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $15
Current: $5.32
Upside: +181.95%
Nov 6, 2025
Maintains: Buy
Price Target: $4 → $5
Current: $2.88
Upside: +73.61%
Oct 14, 2025
Initiates: Buy
Price Target: $12
Current: $0.92
Upside: +1,204.35%
Oct 6, 2025
Assumes: Buy
Price Target: $60
Current: $30.07
Upside: +99.53%
Sep 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.18
Upside: -
Sep 10, 2025
Reiterates: Buy
Price Target: $23
Current: $3.71
Upside: +519.95%
Aug 27, 2025
Maintains: Buy
Price Target: $32 → $40
Current: $4.18
Upside: +856.94%
Aug 15, 2025
Upgrades: Buy
Price Target: $35
Current: $9.41
Upside: +271.94%
Aug 11, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $0.56
Upside: +1,335.24%
Jul 7, 2025
Maintains: Buy
Price Target: $40 → $20
Current: $1.23
Upside: +1,526.02%
Jul 1, 2025
Reiterates: Buy
Price Target: $36
Current: $9.99
Upside: +260.36%
Apr 16, 2025
Maintains: Buy
Price Target: $560 → $280
Current: $8.98
Upside: +3,018.04%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $2.81
Upside: +184.70%
Mar 31, 2025
Reiterates: Buy
Price Target: $30
Current: $2.40
Upside: +1,150.00%
Mar 27, 2025
Reiterates: Buy
Price Target: $18
Current: $2.14
Upside: +741.12%
Mar 26, 2025
Reiterates: Buy
Price Target: $183
Current: $2.87
Upside: +6,262.72%
Mar 26, 2025
Reiterates: Buy
Price Target: $35
Current: $5.33
Upside: +556.66%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.46
Upside: -
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $2.13
Upside: -